drugset / Trial / NCT01762462
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objective: To study the effect of mild and moderate hepatic impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single dose up to 300 mg in subjects with mild and moderate and hepatic impairment and in matched subjects with normal hepatic function.
Timeline
- Start
- 2012-12
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fedratinib | Small molecule | 300 mg | Oral |
Indications
No indication recorded.